Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve

Study Purpose

Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages N/A and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Patient and/or legally authorized representative has agreed to participate in the study by signing the EC-approved consent form, where applicable. 2. Patients (of any age) who underwent or who plan to have a surgical procedure utilizing one of the Codman CERTAS Plus Programmable Valves. 3. Patient (legally designated representative) is willing to comply with the study protocol timelines & requirements. 4. For patients who have had the Codman CERTAS Plus Programmable Valve implanted prior to study enrollment, have available data from implantation to the current time.

Exclusion Criteria:

1. Patients undergoing implantation of the CODMAN CERTAS Plus Programmable Valve as a revision procedure. 2. Patient's planned shunt has distal drainage to the heart. 3. Patient has ventriculitis, peritonitis or meningitis. 4. Patient has sepsis. 5. Patient has a history of poor wound healing. 6. Patient has symptoms pertaining to a skin infection at or near the site of any incisions; an ear infection on either side; a respiratory tract infection; or a urinary tract infection that, in the Investigator's opinion is clinically significant and might compromise the outcome of this study. 7. Patient has had any form of bowel surgery 30 days prior to device implant or anticipates bowel surgery within 90 days following device implant. 8. Patient is otherwise determined by the Investigator to be medically unsuitable for participation in this study. 9. Patient is currently enrolled in another drug or device trial or has been previously entered in this trial. 10. Patient is a prisoner or member of a different vulnerable population that should not be included in the study per the investigator. 11. Patients with known hypersensitivity to rifampin or clindamycin hydrochloride. This criterion applies for patients to be treated with the BACTISEAL Catheters (included in some models of the valve) only.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05397106
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Integra LifeSciences Corporation
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Sherese Fralin, MSN, FNP, PhD
Principal Investigator Affiliation Integra LifeSciences
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Belgium, Germany
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Hydrocephalus, Hydrocephalus in Children, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension, Brain Tumor, Post-Traumatic Hydrocephalus, Hemorrhagic Stroke
Additional Details

The CODMAN CERTAS Plus Programmable Valve is a single use implantable device designed for shunting cerebrospinal fluid (CSF) for the treatment of hydrocephalus. The valve can be set to 8 different performance settings for intraventricular pressure and drainage of CSF. The performance setting of the valve can be set preoperatively and can also be noninvasively changed post-implantation. This clinical investigation will maintain data for each patient from the date of implant through 3 years post-implantation. Data collection for each patient will occur per standard of care. However, the clinical investigation specifically aims to collect and analyze data from the day of procedure, and post-operatively at 1 month, 3 months, 6 months, 12 months, 24 months, and 36 months. Data from follow-up visits will be analyzed according to pre-defined time-intervals referring to these follow-up moments.

Arms & Interventions

Arms

: CODMAN CERTAS Programmable Valves

CODMAN CERTAS Plus Programmable Valve, CODMAN CERTAS Plus Small Inline Programmable Valve, and CODMAN CERTAS Plus Right Angle Programmable Valve.

Interventions

Device: - CODMAN CERTAS Plus Programmable Valve

Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

AZ Delta - Roeselare, Roeselare, Belgium

Status

Not yet recruiting

Address

AZ Delta - Roeselare

Roeselare, ,

Site Contact

Dimitri Vanhauwaert, MD

[email protected]

+ 32 51 237440

Klinikum Dortmund Wirbelsäulenchirurgie, Dortmund, Germany

Status

Recruiting

Address

Klinikum Dortmund Wirbelsäulenchirurgie

Dortmund, ,

Site Contact

Dr. Oliver Müller

[email protected]

339-206-2979

Düsseldorf, Germany

Status

Not yet recruiting

Address

Heinrich Heine University, Dept of Neurosurgery, Universitätsklinik Düsseldorf

Düsseldorf, , 40225

Site Contact

Thomas Beez, MD

[email protected]

+49 211 81 07664

Universitätsklinikum Essen, Essen, Germany

Status

Recruiting

Address

Universitätsklinikum Essen

Essen, ,

Site Contact

Dr. Philipp Dammann

[email protected]

339-206-2979

Freiburg University Hospital, Freiburg, Germany

Status

Recruiting

Address

Freiburg University Hospital

Freiburg, ,

Site Contact

Dr. Mukesch Johannes Shah

[email protected]

339-206-2979

Stuttgart, Germany

Status

Recruiting

Address

Katharinenhospital - Neurochirurgische Klinik Stuttgart

Stuttgart, ,

Site Contact

Dr. Oliver Gandslandt

[email protected]

339-206-2979

Stay Informed & Connected